Satellos says first participant dosed in DMD study

Executive Summary

• Satellos Bioscience Inc. has announced the dosing of the first participant in the "Basecamp" Phase 2 pediatric study for its drug candidate SAT-3247.
• The study is a three-month, randomized, double-blind, placebo-controlled, proof-of-concept trial designed to evaluate the safety, tolerability, and efficacy of SAT-3247 in children with Duchenne muscular dystrophy (DMD).
• The trial aims to assess the drug's potential to regenerate skeletal muscle and improve muscle function, with data potentially serving as a pivotal step in the drug's development.

Key Details

• Study Name: Basecamp
• Drug Candidate: SAT-3247 (proprietary, oral, small molecule drug targeting AAK1 to restore muscle stem cell signaling).
• Indication: Duchenne Muscular Dystrophy (DMD).
• Study Phase: Phase 2 (Proof-of-Concept).
• Study Design: Randomized, double-blind, placebo-controlled.
• Duration: Three months.
• Target Population: 51 ambulatory children aged seven, eight, or nine years old.
• Primary Endpoints: Safety, tolerability, and effect on muscle force.
• Secondary Endpoints: Impact on muscle quality, function, and regeneration.
• Geographic Scope: 25 clinical sites planned across the United States, Europe, the United Kingdom, Australia, Canada, and Serbia.
• Mechanism of Action: SAT-3247 is designed to address deficits in muscle repair and regeneration independent of dystrophin and exon mutation status.

Notable Quotes

• Frank Gleeson, Co-founder and CEO: "Designed as a potential pivotal trial, Basecamp marks a significant step for Satellos in evaluating the therapeutic potential of SAT-3247 in children living with Duchenne. Data generated from Basecamp could play a meaningful role in accelerating the development of SAT-3247 as a novel treatment for this disease."
• Wildon Farwell, MD, Chief Medical Officer: "Basecamp will focus on an important period in Duchenne when muscle health and function begin to decline more rapidly. Treatment options remain limited for this devastating disease, and this study will evaluate a novel approach to potentially increase muscle regeneration and thereby improve function among children with Duchenne."